Cytovance Biologics hires vp of sales and business development

Valerie McDonnell joins from Althea

Cytovance Biologics, a biopharmaceutical contract manufacturing company specialising in the production of therapeutic proteins and antibodies from mammalian cell culture, has appointed Valerie McDonnell as vice president of sales and business development.

McDonnell has more than 22 years’ experience in the biotech industry. Prior to joining Cytovance she was vice president of sales at Althea.

Before joining Althea she was a study director at BioReliance where she was responsible for client programmes in the Molecular Biology Department. She also worked at The Institute for Genomic Research (TIGR) and participated in the Haemophilus influenzae sequencing programme.

You may also like

Manufacturing

Avantor and Cytovance collaborate on plasmid DNA supply

The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy
Manufacturing

Cytovance Biologics to expand microbial manufacturing

Has acquired 100L and 1,000L fermenters
Manufacturing

Cytovance Biologics to expand production capabilities in 2013

Installs a 1,000L SUB bioreactor, 5,000L stainless steel bioreactor and fill/finish line
Manufacturing

Cytovance adds 1,000L bioreactor to mammalian facility

Will complement existing manufacturing process trains in Oklahoma City
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)

Discover how emerging technologies and expert insights are shaping the future of pharma manufacturing
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Subscribe now